Results from the ARCHES trial presented yesterday in San Francisco

On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …

Positive outcomes for apalutamide in the treatment of mHSPC

According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …

Contemporary questions about the initial treatment of advanced forms of prostate cancer

So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …

What is standard, first-line therapy for men with mHSPC today?

A presentation at the ongoing annual meeting of the European  Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Chaarting direction after stampeding along the relevant latitude

So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and publication of data from the LATITUDE trial and the ADT + abiraterone arm of the STAMPEDE trial, … READ MORE …